Eli Lilly and Company announced a collaboration with NVIDIA to build the most powerful supercomputer owned and operated by a pharmaceutical company. This partnership will establish an “AI factory” — a specialized computing infrastructure that manages the entire AI lifecycle, from data ingestion and model training to fine-tuning and large-scale inference.

“Lilly’s mission is to make life better for people around the world, and today that requires excellence not only in science but also in technology,” said Diogo Rau, executive vice president and chief information and digital officer at Lilly. “I don’t believe any other company in our industry is doing what we do at this scale. As a 150-year-old medicine company, one of our most powerful assets is decades of data. With purpose-built AI models, we can set a new scientific standard that accelerates innovation and delivers medicines to more patients, faster.”

The supercomputer, the world’s first NVIDIA DGX SuperPOD with DGX B300 systems, is powered by more than 1,000 B300 GPUs on a unified high-speed networking fabric. This architecture enables seamless communication across GPUs, storage, and related systems on a single network.

Lilly’s new supercomputer and AI factory will allow scientists to train AI models on millions of experiments to test potential medicines, dramatically expanding the scope and sophistication of drug discovery. Many of these proprietary AI models will be accessible on Lilly TuneLab, a collaborative federated AI/ML platform designed to advance drug discovery across the biopharma ecosystem. TuneLab will continue evolving, integrating new workflows that incorporate NVIDIA Clara open-source models.

Beyond discovery, Lilly will leverage the supercomputer to shorten development cycles and accelerate the delivery of medicines. New AI-driven scientific agents will support researchers in reasoning, planning, and collaboration across digital and physical environments. Enhanced medical imaging will offer deeper insights into disease progression, aiding in the development of new biomarkers for personalized care. Manufacturing processes will benefit from digital twins and NVIDIA’s robotic technologies, improving efficiency and minimizing downtime.

“The AI industrial revolution will have its most profound impact on medicine, transforming how we understand biology,” said Kimberly Powell, vice president of health care at NVIDIA. “Modern AI factories are becoming the new instruments of science, shifting discovery from trial-and-error to intentional medicine design. With its strong scientific legacy and commitment to innovation, Lilly stands as a global leader at the forefront of this new era of medical discovery.”

“Lilly is moving beyond using AI as a tool to embracing it as a scientific collaborator,” said Thomas Fuchs, senior vice president and chief AI officer at Lilly. “By embedding intelligence into every layer of our workflows, we are creating an enterprise that learns, adapts, and improves continuously. This is not just about speed — it’s about exploring biology at scale, deepening our understanding of disease, and translating knowledge into meaningful advances for patients and the broader life sciences community.”